372 related articles for article (PubMed ID: 16651889)
21. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.
Klucken J; Ingelsson M; Shin Y; Irizarry MC; Hedley-Whyte ET; Frosch M; Growdon J; McLean P; Hyman BT
Acta Neuropathol; 2006 Feb; 111(2):101-8. PubMed ID: 16482476
[TBL] [Abstract][Full Text] [Related]
22. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.
Pletnikova O; West N; Lee MK; Rudow GL; Skolasky RL; Dawson TM; Marsh L; Troncoso JC
Neurobiol Aging; 2005; 26(8):1183-92. PubMed ID: 15917102
[TBL] [Abstract][Full Text] [Related]
23. Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases.
Dalfó E; Ferrer I
Neurobiol Aging; 2008 Mar; 29(3):408-17. PubMed ID: 17166629
[TBL] [Abstract][Full Text] [Related]
24. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
Sierra M; Gelpi E; Martí MJ; Compta Y
Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
[TBL] [Abstract][Full Text] [Related]
25. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease.
Williams MM; Xiong C; Morris JC; Galvin JE
Neurology; 2006 Dec; 67(11):1935-41. PubMed ID: 17159097
[TBL] [Abstract][Full Text] [Related]
26. Striatal beta-amyloid deposition in Parkinson disease with dementia.
Jellinger KA
J Neuropathol Exp Neurol; 2008 May; 67(5):484; author reply 484-5. PubMed ID: 18451728
[No Abstract] [Full Text] [Related]
27. Neuronal hemoglobin is reduced in Alzheimer's disease, argyrophilic grain disease, Parkinson's disease, and dementia with Lewy bodies.
Ferrer I; Gómez A; Carmona M; Huesa G; Porta S; Riera-Codina M; Biagioli M; Gustincich S; Aso E
J Alzheimers Dis; 2011; 23(3):537-50. PubMed ID: 21157025
[TBL] [Abstract][Full Text] [Related]
28. Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study.
Wakisaka Y; Furuta A; Tanizaki Y; Kiyohara Y; Iida M; Iwaki T
Acta Neuropathol; 2003 Oct; 106(4):374-82. PubMed ID: 12904992
[TBL] [Abstract][Full Text] [Related]
29. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies.
Kasanuki K; Iseki E; Fujishiro H; Yamamoto R; Higashi S; Minegishi M; Togo T; Katsuse O; Uchikado H; Furukawa Y; Hino H; Kosaka K; Sato K; Arai H
J Neurol Sci; 2012 Mar; 314(1-2):111-9. PubMed ID: 22041339
[TBL] [Abstract][Full Text] [Related]
30. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
[TBL] [Abstract][Full Text] [Related]
31. Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia.
Jellinger KA
Neurodegener Dis; 2008; 5(3-4):118-21. PubMed ID: 18322367
[TBL] [Abstract][Full Text] [Related]
32. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.
Higashi S; Iseki E; Yamamoto R; Minegishi M; Hino H; Fujisawa K; Togo T; Katsuse O; Uchikado H; Furukawa Y; Kosaka K; Arai H
Brain Res; 2007 Dec; 1184():284-94. PubMed ID: 17963732
[TBL] [Abstract][Full Text] [Related]
33. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
[TBL] [Abstract][Full Text] [Related]
34. Alpha-synuclein, Abeta and Alzheimer's disease.
Wirths O; Bayer TA
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):103-8. PubMed ID: 12551731
[TBL] [Abstract][Full Text] [Related]
35. Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies.
Colom-Cadena M; Gelpi E; Charif S; Belbin O; Blesa R; Martí MJ; Clarimón J; Lleó A
J Neuropathol Exp Neurol; 2013 Dec; 72(12):1203-12. PubMed ID: 24226269
[TBL] [Abstract][Full Text] [Related]
36. I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies.
Sieczkowski E; Milenkovic I; Venkataramani V; Giera R; Ströbel T; Höftberger R; Liberski PP; Auff E; Wirths O; Bayer TA; Kovacs GG
J Alzheimers Dis; 2015; 44(1):103-14. PubMed ID: 25182745
[TBL] [Abstract][Full Text] [Related]
37. alpha-Synucleinopathy in the human olfactory system in Parkinson's disease: involvement of calcium-binding protein- and substance P-positive cells.
Ubeda-Bañon I; Saiz-Sanchez D; de la Rosa-Prieto C; Argandoña-Palacios L; Garcia-Muñozguren S; Martinez-Marcos A
Acta Neuropathol; 2010 Jun; 119(6):723-35. PubMed ID: 20383714
[TBL] [Abstract][Full Text] [Related]
38. Lewy body-related alpha-synucleinopathy in the aged human brain.
Jellinger KA
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1219-35. PubMed ID: 15480835
[TBL] [Abstract][Full Text] [Related]
39. Neuropathological investigation of hypocretin expression in brains of dementia with Lewy bodies.
Kasanuki K; Iseki E; Kondo D; Fujishiro H; Minegishi M; Sato K; Katsuse O; Hino H; Kosaka K; Arai H
Neurosci Lett; 2014 May; 569():68-73. PubMed ID: 24704327
[TBL] [Abstract][Full Text] [Related]
40. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia.
Bombois S; Maurage CA; Gompel M; Deramecourt V; Mackowiak-Cordoliani MA; Black RS; Lavielle R; Delacourte A; Pasquier F
Arch Neurol; 2007 Apr; 64(4):583-7. PubMed ID: 17420322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
